Katy Tsai, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address1825 4th Street
San Francisco CA 94158
Phone415-502-5483
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown UniversityM.D.2010Alpert Medical School
    UNC Chapel HillResidency2013Internal Medicine
    UCSFFellowship2016Medical Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Katy K. Tsai is a medical oncologist and clinical researcher who specializes in treating advanced melanoma and other non-melanoma skin cancers, such as squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma.

    Dr. Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow, before joining UCSF faculty in the Melanoma & Skin Cancer Program.

    Dr. Tsai is deeply committed to finding the best possible treatment options for her patients. As Site Committee Chair for her program, she works closely with her medical oncology, surgical oncology, and dermatology/dermatopathology colleagues to develop novel clinical trial options, and is also responsible for the curation of the Melanoma & Skin Cancer Program's clinical trial portfolio. She has a long-standing research interest in melanoma survivorship and in understanding the pathophysiology and best treatment practices for acute and chronic immune-related adverse events (irAEs).

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. Eur J Cancer. 2021 Jun 28; 153:213-222. Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM. PMID: 34214936.
      View in: PubMed   Mentions:    Fields:    
    2. Mechanisms of Cardiovascular Toxicities Associated with Immunotherapies. Circ Res. 2021 May 03. Baik A, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. PMID: 33934609.
      View in: PubMed   Mentions:    Fields:    
    3. Loneliness and symptom burden in oncology patients during the COVID-19 pandemic. Cancer. 2021 Apr 27. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno HT, Chang SM, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Kober KM, Laffan A, Levine JD, Pozzar R, Rhoads K, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 33905528.
      View in: PubMed   Mentions:    Fields:    
    4. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J Exp Med. 2021 Apr 05; 218(4). Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, Sharpe AH, Singer M. PMID: 33651880.
      View in: PubMed   Mentions: 3     Fields:    
    5. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond). 2021 Mar 12; 135(5):703-724. Baik AH, Tsai KK, Oh DY, Aras MA. PMID: 33686402.
      View in: PubMed   Mentions:    Fields:    
    6. Multidisciplinary Management of Cancer During Pregnancy. JCO Oncol Pract. 2020 09; 16(9):545-557. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, Van Loon K. PMID: 32910882.
      View in: PubMed   Mentions:
    7. Oncology patients' perceptions of and experiences with COVID-19. Support Care Cancer. 2021 Apr; 29(4):1941-1950. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 32809060.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    8. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4122-4130. Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI. PMID: 32488521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020 06; 8(1). Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. PMID: 32581057.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 06 15; 26(12):2827-2837. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. PMID: 32376655.
      View in: PubMed   Mentions: 7     Fields:    
    11. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. PMID: 32228358.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    12. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 04; 31(4):532-540. Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. PMID: 32147213.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    13. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 02; 8(2):246-254. Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. PMID: 31852717.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    14. PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. J Natl Compr Canc Netw. 2019 07 01; 17(7):778-783. Tsai KK, Khurana N, McCalmont T, Daud A, Bastian B, Yeh I. PMID: 31319387.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019 Mar 01; 38(1):E67-E74. Fitzgerald K, Tsai KK. PMID: 31051028.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    17. Obstacles to improving outcomes in the treatment of uveal melanoma. Cancer. 2018 07 01; 124(13):2693-2703. Tsai KK, Bollin KB, Patel SP. PMID: 29579316.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    18. Tyrosine Kinase Inhibitors and Male Reproductive Health. Clin Pharmacol Ther. 2017 Nov; 102(5):754-756. Ramstein JJ, Tsai KK, Smith JF. PMID: 28791688.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. PMID: 28724802.
      View in: PubMed   Mentions: 17     Fields:    
    20. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 07; 22(7):823-833. Daud A, Tsai K. PMID: 28526719.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    21. Are PD-1 antibodies safe for use in metastatic uveal melanoma? Melanoma Manag. 2017 May; 4(2):79-82. Tsai KK, Algazi AP. PMID: 30190908.
      View in: PubMed   Mentions:
    22. Melanoma Management. Are PD-1 antibodies safe for use in metastatic uveal melanoma?. 2017; 4(2):79-82. Tsai KK, Algazi AP.
    23. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCellsCTClinical Trials
    24. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A. PMID: 28324889.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    25. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 02 01; 28(2):368-376. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. PMID: 27687304.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    26. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. PMID: 27660712.
      View in: PubMed   Mentions: 10     Fields:    
    27. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. PMID: 27533448.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    28. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. PMID: 27533633.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    29. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 09 01; 126(9):3447-52. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. PMID: 27525433.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCells
    30. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015 Oct 31; 8:123. Tsai KK, Daud AI. PMID: 26518223.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    31. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75. Tsai KK, Daud AI. PMID: 25802230.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    32. Implementation Science Workshop: primary care-based multidisciplinary readmission prevention program. J Gen Intern Med. 2014 May; 29(5):798-804. Cavanaugh JJ, Jones CD, Embree G, Tsai K, Miller T, Shilliday BB, McGuirt B, Roche R, Pignone M, DeWalt DA, Ratner S. PMID: 24687289.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    33. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014; 10(11):3111-6. Tsai KK, Zarzoso I, Daud AI. PMID: 25625924.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    34. Association between obesity, sexual activity and sexual function in women with pelvic floor disorders. Female Pelvic Med Reconstr Surg. 2010 Nov; 16(6):331-5. Tsai KK, Marques F, Myers DL, Sung VW. PMID: 22453616.
      View in: PubMed   Mentions: 2     Fields:    
    35. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother. 2010 Jul; 65(7):1460-5. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y. PMID: 20430790.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    Katy's Networks
    Concepts (145)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (44)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.0.0-839-g49dc76ac on PROFILES-PWEB01.

    Copyright © The Regents of the University of California